Loading clinical trials...

Cross-cultural Adaptation and Validation of the P-CIN for Chinese Pediatric Oncology Patients | Clinical Trials | Clareo Health

COMPLETED

Cross-cultural Adaptation and Validation of the P-CIN for Chinese Pediatric Oncology Patients

Cross-cultural Adaptation and Validation of the Pediatric Chemotherapy-induced Neuropathy (P-CIN) for Chinese Pediatric Oncology Patients: A Multi-center Study

NCT07053579•The Hong Kong Polytechnic University

View on ClinicalTrials.gov

Summary

The goal of this study was to conduct a cross-cultural adaptation of the P-CIN into the Chinese context, assess its psychometric properties, and determine the cut-off value of CIPN among Chinese pediatric oncology patients. Participants provided demographic and clinical characteristics, and complete the translated P-CIN, Wong-baker FACES Pain Rating scale for pain, and Chinese version of the Pediatric Quality of Life Inventory (PedsQL) Cancer Module for quality of life.

Detailed Description

A methodological, descriptive study was conducted.

Eligibility

Age

6 - 18 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•(1) 6 to 18 years of age
•(2) were diagnosed with cancer
•(3) had received or were currently receiving neurotoxic chemotherapy drugs (e.g., Vincristine, Cisplatin, Carboplatin, Oxaliplatin, Paclitaxel, Docetaxel, Ixabepilone, Bortezomib, Thalidomide)
•(4) were able to communicate, read, and write in Chinese without significant hearing and vision problems to ensure they understood the P-CIN.

Exclusion Criteria

•(1) had a diagnosis of cancer in the central nervous system (CNS) cancer, cancer relapse or secondary cancer
•(2) in the terminal stage
•(3) planned to receive multiple cancer treatment (e.g., radiotherapy and immunotherapy)
•(4) suffered from other neuromuscular diseases (e.g., traumatic brain injury and cerebral palsy)
•(5) had a developmental deficit (e.g., Down's syndrome and other chromosomal disorders)
•(6) have suffered from psychiatric diseases or used antipsychotic drugs
•(7) had peripheral neuropathy symptoms caused by diabetes, genetic diseases, spinal cord injury, or alcoholism, or
•(8) had other neuromuscular disorders (e.g., traumatic brain injury, cerebral palsy).

Locations (2)

Ka Yan Ho

Hong Kong, China, Hong Kong

The Hong Kong Polytechnic University

Hong Kong, Hong Kong

Key Dates

Start Date

January 5, 2025

Primary Completion Date

May 30, 2025

Completion Date

May 30, 2025

Last Updated

July 8, 2025

Enrollment

313

ACTUAL participants

Conditions

Pediatric Cancer

Lurbinectedin in FET-Fused Tumors

NCT05918640

Ewing SarcomaDesmoplastic Small Round Cell Tumor+2 more

View study

RECRUITING

Real World Pediatric Oncology Rehabilitation in Italy ( ReWori )

NCT07368582

Pediatric CancerPediatric Cancer Patients+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 8, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cross-cultural Adaptation and Validation of the P-CIN for Chinese Pediatric Oncology Patients

Inclusion Criteria

Exclusion Criteria

Lurbinectedin in FET-Fused Tumors

Real World Pediatric Oncology Rehabilitation in Italy ( ReWori )

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Decision Support Intervention of Minor Cancer Patients and Their Parents

Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention